Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Saab on Napabucasin (BBI-608) in Colorectal Cancer Treatment

June 20th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

Gastroesophageal Cancer: Emerging Approaches

June 20th 2017

Patient Selection for Immunotherapy in Gastric Cancer

June 20th 2017

Checkpoint Inhibition in Gastroesophageal Cancers

June 20th 2017

Beyond Progression in HER2-Positive Gastric/GEJ Cancers

June 20th 2017

Antiangiogenesis in Gastric/GEJ Cancers: A Global View

June 20th 2017

Long-term Strategies in Gastric Cancer

June 20th 2017

Sequencing Decisions in Gastric Cancers

June 20th 2017

Relapse Following FLOT in Gastric/GEJ Cancer

June 20th 2017

Curative Intent in Locally Advanced Gastroesophageal Cancer

June 20th 2017

The Potential Impact of FLOT4 in Gastroesophageal Cancer

June 20th 2017

FLOT4: Perioperative Strategies in Gastroesophageal Cancer

June 20th 2017

Gastroesophageal Cancer: Diagnostic Workup

June 20th 2017

Biology and Location of Gastroesophageal Cancers

June 20th 2017

Current Molecular Profiling in Gastric Cancers

June 20th 2017

Global Trends in Gastroesophageal Cancers

June 20th 2017

Dr. Diaz on Pembrolizumab for CRC

June 20th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

test-1

June 17th 2017

Dr. Bekaii-Saab on Napabucasin Plus Nab-paclitaxel/Gemcitabine in Pancreatic Cancer

June 16th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses a phase I study of napabucasin plus nab-paclitaxel (Abraxane) and gemcitabine for the treatment of patients with pancreatic cancer.

Hopeful Signs in Pancreatic Cancer

June 13th 2017

Although the prognosis for patients with pancreatic cancer is often grim, there have been noteworthy improvements in outcomes through the use of current chemotherapies.